P851: Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Muñoz Villafranca, M.D.C.(1)*;Merino , O.(2);Gómez , L.(2);Higuera, R.O.(1);Arreba , P.(1);Nagore, D.(3);Ruiz-Argüello, B.(3);Gorostiza, I.(4);López, M.L.(1);Ortiz de Zárate, J.(1);
(1)Hospital Universitario de Basurto, Gastroenterology, Bilbao, Spain;(2)Hospital Universitario de Cruces, Gastroenterology, Barakaldo, Spain;(3)Progenika Biopharma-Grifols, Biochemestry, Bilbao, Spain;(4)Hospital Universitario de Basurto, Research Unit, Bilbao, Spain;
P852: Metataxonomic and metabolomic profiling to predict response to anti-TNF therapy in Crohn’s DiseaseECCO'24Year: 2024
Authors: Foyzul, J.(1)*;Alexander, J.L.(1,2);Chappell, K.E.(1);Ibraheim, H.A.(1,2);Saifuddin, A.(1,3);Kennedy, N.A.(4,5);Bewshea, C.(4);Lin, S.(4,5);Hart, A.L.(3);Goodhand, J.R.(3,5);Ahmad, T.(4,5);Powell, N.(1,2);
(1)Imperial College London, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;(2)Imperial College Healthcare NHS Trust, Department of Gastroenterology, London, United Kingdom;(3)St Marks Hospital and Academic Institute- Gastroenterology, Department of Gastroenterology, London, United Kingdom;(4)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(5)Royal Devon University Healthcare NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom;UK Inflammatory Bowel Disease Pharmacogenetics Study Group
P853: Factors associated with intestinal tissue levels of anti-TNF in pediatric patients with Crohn@E@s DiseaseECCO'24Year: 2024
Authors: Dotlacil, V.(1)*;Coufal, S.(2);Lerchova, T.(3);Zarubova, K.(3);Kucerova, B.(1);Tlaskalova-Hogenova, H.(2);Kverka, M.(2);Bronsky, J.(3);Skaba, R.(1);Hradsky, O.(3);Rygl, M.(1);
(1)Charles University and Motol University Hospital, Department of Pediatric Surgery, Prague, Czech Republic;(2)Institute of Microbiology- Czech Academy of Sciences, Laboratory of Cellular and Molecular Immunology, Prague, Czech Republic;(3)Charles University and Motol University Hospital, Department of Pediatrics, Prague, Czech Republic;
P854: Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitisECCO'24Year: 2024
Authors: Khoo, E.(1,2)*;Amiss, A.(3);Ding, J.N.(4);Bryant, R.(5);Mohsen, W.(6);Connor, S.(7);Leung, R.(8);Croft, A.(9);Lynch, K.(10);Sparrow, M.(11);De Cruz, P.(12);An, Y.K.(1,2);Holtmann, G.(13);Begun, J.(1,2,3);
(1)Mater Hospital Brisbane, Department of Gastroenterology, South Brisbane, Australia;(2)The University of Queensland, Faculty of Medicine, St Lucia, Australia;(3)Mater Research, Inflammatory Bowel Disease, Woolloongabba, Australia;(4)St Vincent@E@s Hospital Melbourne, Department of Gastroenterology, Fitzroy, Australia;(5)The Queen Elizabeth Hospital, Department of Gastroenterology, Woodville South, Australia;(6)Gold Coast University Hospital, Department of Gasteroenterology, Southport, Australia;(7)Liverpool Hospital, Department of Gastroenterology, Liverpool, Australia;(8)Macquarie University Hospital, Department of Gastroenterology, Macquarie University, Australia;(9)Royal Brisbane and Women Hospital, Department of Gastroenterology, Herston, Australia;(10)Royal Adelaide Hospital, Department of Gastroenterology, Adelaide, Australia;(11)The Alfred, Department of Gastroenterology, Melbourne, Australia;(12)Austin Hospital, Department of Gastroenterology, Heidelberg, Australia;(13)Princess Alexandra Hospital, Department of Gastroenterology, Woolloongabba, Australia;
P855: Have biological agents changed the need for abdominal surgery in inflammatory bowel disease over time?ECCO'24Year: 2024
Authors: Suria, C.(1)*;Bosca-Watts, M.M.(1);García-Trueba, A.(2);Tosca, J.(1);Antón, C.(3);Sanahuja, A.(3);Merino, V.(3);Abril, C.(1);Ballester, M.P.(1);Romero, E.(1);Marti, D.(1);Galvez, C.(4);Ponce, M.(4);Pascual, I.(1);
(1)Clinic University Hospital of Valencia, Digestive Disease Department, Valencia, Spain;(2)University of Valencia, Digestive Disease Department, Valencia, Spain;(3)Clinic University Hospital of Valencia, Digestive Disease Deparment, Valencia, Spain;(4)Clinic University Hospital of Valencia, Endoscopy Department, Valencia, Spain;IBD Unit
P856: Influential factors on the clinical and radiological closure of resistant perianal fistula treated with stomaECCO'24Year: 2024
Authors: Candan , S.(1)*;Bakkaloglu , O.K.(2);Bayar , M.(3);Eskazan , T.(1);Hatemi , I.(4);Erzin , Y.(1);Celik , A.F.(1);
(1)Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey;(2)KOŞUYOLU HIGH SPECIALIZATION EDUCATION AND RESEARCH HOSPITAL, Gastroenterology, istanbul, Turkey;(3)Istanbul Universit Cerrahpasa - Cerrahpasa Medical Faculty, Internal Medicine, Istanbul, Turkey;(4)Istnabul University Cerrahpasa - Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey;
P857: Effectiveness and safety of subcutaneous infliximab in perianal Crohn@E@s disease: a multicentre cohort studyECCO'24Year: 2024
Authors: Andre, M.(1);Kirchgesner, J.(2);Laharie, D.(3);Guillo, L.(4);Abramowitz, L.(5);Seksik, P.(6);Nachury, M.(7);Fumery, M.(8);Amil, M.(9);Nancey, S.(10);Le Berre, C.(11);Moussata, D.(12);Buisson, A.(13);Fathallah, N.(14);Gilletta, C.(15);Uzzan, M.(16);Duveau, N.(17);Peyrin-Biroulet, L.(18);Nahon , S.(19);Savoye, G.(20);Charkaoui, M.(21);Vicaut, E.(22);Vuitton, L.(1)*;
(1)CHU Besançon, Department of Gastroenterology, Besançon, France;(2)APHP Saint Antoine, Gastroenterology, Paris, France;(3)CHU Bordeaux, Hepatogastroenterology, Bordeaux, France;(4)APHM Hopital Nord, Department of Gastroenterology, Marseille, France;(5)APHP Hopital Bichat, Department of Gastroenterology, Paris, France;(6)APHP Hopital Saint-Antoine, Department of Gastroenterology, Paris, France;(7)CHU Lille, Hepatogastroenterology, Lille, France;(8)CHU Amiens, Hepatogastroenterlogy, Amiens, France;(9)CH Vendée, Department of Gastroenterology, La Roche Sur Yon, France;(10)CHU Lyon Sud, Department of Gastroenterology, Lyon, France;(11)CHU Nantes, Department of Gastroenterology, Nantes, France;(12)CHU Tours, Department of Gastroenterology, Tours, France;(13)CHU Clermont-Ferrand, Department of Gastroenterology, Clermont-Ferrand, France;(14)Hopital Saint-Joseph, Department of Gastroenterology, Paris, France;(15)CHU Toulouse, Department of Gastroenterology, Toulouse, France;(16)APHP Hopital Mondor, Department of Gastroenterology, Créteil, France;(17)CH Roubaix, Department of Gastroenterology, Roubaix, France;(18)CHU Nancy, Department of Gastroenterology, Nancy, France;(19)CH Montfermeil, Department of Gastroenterology, Montfermeil, France;(20)CH Rouen, Department of Gastroenterology, Rouen, France;(21)CHU Dijon, Department of Gastroenterology, Dijon, France;(22)APHP, Methodology, Paris, France;
P858: Real World Outcomes of Dual Advanced Therapy in Inflammatory Bowel Disease in Children and Young AdultsECCO'24Year: 2024
Authors: Kellar, A.(1)*;Dolinger, M.(2);Spencer, E.(2);Dubinsky, M.(2);
(1)University of Chicago, Section of Pediatric Gastroenterology- Hepatology and Nutrition, Chicago, United States;(2)Icahn School of Medicine at Mount Sinai, Division of Pediatric Gastroenterology- Susan and Leonard Feinstein IBD Clinical Center, New York, United States;
P859: Sodium Butyrate supplementation significantly improved clinical outcomes and quality of life in patients with Crohn’s Disease – results from a randomized placebo-controlled studyECCO'24Year: 2024
Authors: Facchin PhD, S.(1);Calgaro , M.(2);Pandolfo , M.(2);De Barba , C.(1)*;Barberio , B.(1);Zingone , F.(1);Vitulo , N.(2);Savarino , E.V.(1);
(1)University of Padua, Surgical- Oncology and Gastroenterology, Padua, Italy;(2)University of Verona, Department of Biotechnology, Verona, Italy;
P860: Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis - a six-year follow-up studyECCO'24Year: 2024
Authors: Gros, B.(1,2)*;Ross, H.(1);Nwabueze, M.(1);Constantine-Cooke, N.(3,4);Derikx, L.A.(1,5,6);Lyons, M.(1);O@E@Hare, C.(1,7);Noble, C.(1);Arnott, I.D.(1);Jones, G.R.(1,8);Lees, C.W.(1,9);Plevris, N.(1);
(1)Western General Hospital, Edinburgh IBD Unit, Edinburgh, United Kingdom;(2)Reina Sofía University Hospital, Gastroenterology and Hepatology, Cordoba, Spain;(3)Western General Hospital, MRC Human Genetics Unit- Institute of Genetics and Cancer- University of Edinburgh, Edinburgh, United Kingdom;(4)Western General Hospital, Centre for Genomics and Experimental Medicine- Institute of Genetics and Cancer- University of Edinburgh, Edinburgh, United Kingdom;(5)Erasmus MC- University Medical Centre Rotterdam, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(6)Radboud University Medical Center, Inflammatory Bowel Disease Center- Department of Gastroenterology and Hepatology-, Nijmegen, The Netherlands;(7)Western General Hospital, Edinburgh Pharmacy Unit, Edinburgh, United Kingdom;(8)The Queen@E@s Medical Research Institute- University of Edinburgh, Centre for Inflammation Research, Edinburgh, United Kingdom;(9)Institute of Genetics and Cancer- University of Edinburgh- Western General Hospital, Centre for Genomics and Experimental Medicine, Edinburgh, United Kingdom;
P862: Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trialsECCO'24Year: 2024
Authors: Panés, J.(1)*;Loftus Jr., E.V.(2);Armuzzi, A.(3);Siegmund, B.(4);Sands, B.E.(5);Boland, B.S.(6);Kalabic, J.(7);Lai, J.H.(8);Sharma, D.(7);Remple, V.(7);Sanchez Gonzalez, Y.(7);Lindsay, J.O.(9);
(1)Hospital Clínic Barcelona, IDIBAPS- CIBERehd, Barcelona, Spain;(2)Mayo Clinic College of Medicine and Science, none, Rochester, United States;(3)Humanitas University, Inflammatory Bowel Disease Center- IRCCS Humanitas Research Hospital, Milan, Italy;(4)Charité Universitätsmedizin Berlin, Medical Department- Division of Gastroenterology- Infectiology and Rheumatology, Berlin, Germany;(5)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(6)University of California- San Diego, Department of Medicine, San Diego, United States;(7)AbbVie Inc., none, North Chicago, United States;(8)AbbVie Inc.and Health Outcomes Division- College of Pharmacy- The University of Texas at Austin, none, Austin, United States;(9)Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom;
P863: Prospective outcome following ustekinumab treatment in a real-world cohort of inflammatory bowel disease patients.ECCO'24Year: 2024
Authors: Ramos Lopez, L.(1)*;Ramos-Díaz, R.(2);Benítez-Zafra, F.(3);Morant-Domínguez, A.(3);Vera-Santana , B.(3);Mourani-Padrón, I.(4);Alonso-Abreu, I.(5);Carrillo-Palau, M.(5);Reygosa , C.(5);Medina-Chico , J.S.(6);Gutierrez-Nicolás, F.(7);Nazco-Casariego, J.(7);Hernández-Guerra, M.(3);
(1)Hospital Universitario De Canarias, IBD Unit. Gastroenterology Department, Santa Cruz De Tenerife, Spain;(2)Hospital Universitario de Canarias, Reasearch Unit Fundación Canaria Instituto de Investigación Sanitaria de Canarias FIISC- La Laguna- Spain., La Laguna, Spain;(3)Hospital Universitario de Canarias, Gastroenterology Department, La Laguna, Spain;(4)Hospital Universitario de Canarias, Research Unit Fundación Canaria Instituto de Investigación Sanitaria de Canarias FIISC- La Laguna- Spain., La Laguna, Spain;(5)Hospital Universitario de Canarias, IBD Unit. Gastroenterology Department, La Laguna, Spain;(6)Hospital Universitario de Canarias, Specialist Nurse.IBD Unit. Gastroenterology Department, La Laguna, Spain;(7)Hospital Universitario de Canarias, Hospital Pharmacy Department, La Laguna, Spain;
P864: The Effect of Ustekinumab on Mucosal Inflammation in Paediatric Crohn’s Disease: The REALITI Real-World Evidence Effectiveness StudyECCO'24Year: 2024
Authors: Adler, J.(1);Steiner, S.(2)*;Saeed, S.(3);Colletti, R.(4);Strauss, R.(5);Godwin, B.(6);Sheahan, A.(7);Zhang, R.(7);Kim, L.(8);Xiao, Y.(9);Volger, S.(5);
(1)University of Michigan, C.S. Mott Children@E@s Hospital- Michigan Medicine, Ann Arbor- MI, United States;(2)Indiana University Health, Riley Hospital for Children, Carmel- IN, United States;(3)Wright State University, Dayton Children’s Hospital, Dayton- OH, United States;(4)University of Vermont, Children@E@s Hospital, Burlington- VT, United States;(5)Janssen Research & Development- LLC, Pediatric Development Team, Spring House- PA, United States;(6)Janssen Research & Development- LLC, Pediatric Development Team-, Spring House- PA, United States;(7)Janssen Research & Development- LLC, Immunology Epidemiology, Titusville- NJ, United States;(8)Janssen Research & Development- LLC, Statistics and Decision Sciences, Spring House- PA, United States;(9)Cytel, n/a, Waltham- MA, United States;
P865: Screening for low-processed breads - compositional analysis of food additives used in commercially available breadsECCO'24Year: 2024
Authors: Shakhman, S.(1,2)*;Pfeffer-Gik, T.(1,2);Elial-Fatal, S.(1);Broitman, Y.(1,3);Yanai, H.(1,3);Gophna, U.(4);Dotan, I.(1,3);Godny, L.(1,2);
(1)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(2)Rabin Medical Center, Nutrition unit, Petah Tikva, Israel;(3)Tel Aviv University, Faculty of Medicine, Tel Aviv, Israel;(4)Tel Aviv University, The Shmunis School of Biomedicine and Cancer Research, Tel Aviv, Israel;
P866: Management of fistulizing Crohn@E@s Disease in a moroccan population: about 125 casesECCO'24Year: 2024
Authors: Aouroud, H.(1)*;Aouroud, M.(1);Lairani, F.E.(1);Nacir, O.(1);Ait errami, A.(1);Oubaha, S.(1);Samlani, Z.(1);Krati, K.(1);
(1)Mohamed VI UNIVERSITY HOSPITAL, Gastro-enterology, Marrakech, Morocco;
P867: Abdominally targeted yoga-based physical exercises as a therapeutic intervention for Inflammatory Bowel DiseasesECCO'24Year: 2024
Authors: Izhar, R.(1,2)*;Werner , L.(1,2);Fibelman, M.(1,2);Shapiro, I.(3,4);Siderskyi, A.(5);Ostrinski, Y.(6,7);Hirsch , A.(1,2);Ron , Y.(1,2);Fliss Isakov, N.(1,2);Maharshak, N.(1,2);
(1)Tel Aviv Sourasky Medical Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;(2)Tel Aviv University, School of Medicine, Tel Aviv, Israel;(3)Ostmed, Ostmed, Tel Aviv, Israel;(4)Rami Clinic, Rami Clinic, St. Petersburg, Russian Federation;(5)Yoga Workout Self-Adjustment System, Self-Adjustment System, Kiev, Ukraine;(6)Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, Ramat Gan, Israel;(7)Rīga Stradiņš University, Institute of Microbiology and Virology, Rīga, Latvia;
P869: Deep ulcers in acute Ulcerative Colitis at index endoscopy predict corticosteroid resistanceECCO'24Year: 2024
Authors: Goncalves, J.(1,2,3)*;Macedo Silva, V.(1,2,3);Macedo, C.(1,2,3);Arieira, C.(1,2,3);Cúrdia Gonçalves, T.(1,2,3);Dias Castro, F.(1,2,3);Magalhães, J.(1,2,3);João Moreira, M.(1,2,3);Cotter, J.(1,2,3);
(1)Hospital da Senhora da Oliveira, Gastroenterology, Guimarães, Portugal;(2)Life and Health Sciences Research Institute ICVS- School of Medicine, University of Minho, Braga, Portugal;(3)ICVS/3B@E@s, PT Government Associate Laboratory, Braga/Guimarães, Portugal;
P870: Effectiveness and safety of adalimumab as first line biological treatment in Ulcerative ColitisECCO'24Year: 2024
Authors: López Cardona, J.(1)*;Sharma, E.(2);Lal, N.(2);Anderson, S.(2);Dart, R.(2);Mawdsley, J.(2);Ray, S.(2);Samaan, M.(2);Irving, P.(2);
(1)Hospital Universitario Ramón y Cajal, Gastroenterología y Hepatología, Madrid, Spain;(2)Guy’s and St Thomas’ NHS Foundation Trust, IBD Centre, London, United Kingdom;
P871: A modified Crohn’s disease exclusion diet in a multi-ethnic Asian settingECCO'24Year: 2024
Authors: Tan, C.K.(1)*;Wong, A.(2);Huang, Y.(2);Ling, K.L.(1);Wang, L.M.(3);Ang, T.L.(1);Ong, J.(1);
(1)Changi General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore;(2)Changi General Hospital, Department of Dietetics, Singapore, Singapore;(3)Changi General Hospital, Department of Laboratory Medicine, Singapore, Singapore;
